Aeglea Bio Therapeutics Stock EBITDA
Aeglea Bio Therapeutics fundamentals help investors to digest information that contributes to Aeglea Bio's financial success or failures. It also enables traders to predict the movement of Aeglea Stock. The fundamental analysis module provides a way to measure Aeglea Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeglea Bio stock.
Aeglea |
Aeglea Bio Therapeutics Company EBITDA Analysis
Aeglea Bio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Aeglea Bio EBITDA | (84.78 M) |
Most of Aeglea Bio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeglea Bio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Aeglea Bio Therapeutics reported earnings before interest,tax, depreciation and amortization of (84.78 Million). This is 109.66% lower than that of the Biotechnology sector and 184.65% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.17% higher than that of the company.
Aeglea EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeglea Bio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics of similar companies.Aeglea Bio is currently under evaluation in ebitda category among its peers.
Aeglea Fundamentals
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Shares Owned By Insiders | 2.40 % | |||
| Shares Owned By Institutions | 97.60 % | |||
| Number Of Shares Shorted | 128.62 K | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 4.08 X | |||
| Revenue | 2.33 M | |||
| Gross Profit | (262 K) | |||
| EBITDA | (84.78 M) | |||
| Net Income | (83.81 M) | |||
| Cash And Equivalents | 73.68 M | |||
| Cash Per Share | 1.20 X | |||
| Total Debt | 4.63 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.65 X | |||
| Book Value Per Share | (60.61) X | |||
| Cash Flow From Operations | (80.14 M) | |||
| Short Ratio | 2.84 X | |||
| Earnings Per Share | (74.15) X | |||
| Target Price | 17.5 | |||
| Number Of Employees | 69 | |||
| Beta | 2.57 | |||
| Market Capitalization | 45.59 M | |||
| Total Asset | 71.14 M | |||
| Retained Earnings | (425.62 M) | |||
| Working Capital | 47.6 M | |||
| Current Asset | 38.29 M | |||
| Current Liabilities | 2.52 M | |||
| Z Score | -5.56 | |||
| Net Asset | 71.14 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |